Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of LY2189265 on the Pharmacokinetics of Atorvastatin in Healthy Subjects.

Next Previous
Trial Profile

Effect of LY2189265 on the Pharmacokinetics of Atorvastatin in Healthy Subjects.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 17 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dulaglutide (Primary) ; Atorvastatin
  • Indications Atrial fibrillation; Cardiovascular disorders; Diabetic foot ulcer; Heart failure; Hypercholesterolaemia; Hyperlipoproteinaemia type II; Hyperlipoproteinaemia type III; Hypertriglyceridaemia; Low HDL cholesterol; Neurological disorders; Retinal vascular occlusion; Systemic lupus erythematosus; Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Eli Lilly and Company

    • Most Recent Events

    • 29 Mar 2017 Results of pooled analysis from four trials (NCT01458210, NCT01436201, NCT01432938, and NCT01250834) assessing the effect of dulaglutide on PK of digoxin, warfarin, atorvastatin and Ortho-Cyclen and PD of warfarin, published in the Clinical Pharmacokinetics
    • 11 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 22 Feb 2011 Planned End Date changed from 1 Apr 2011 to 1 Mar 2011 as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top